Chemists Hail Govt Move to Slash Cancer Drug Prices
AIOCD welcomes the government's move to cap trade margins on anti-cancer medicines, potentially saving patients Rs 2,500 crore annually.
The All India Organisation of Chemists & Druggists (AIOCD) has officially welcomed the Indian government's landmark decision to rationalise trade margins on non-scheduled anti-cancer medicines. This strategic move is being hailed as a massive victory for patient accessibility, aimed at making life-saving treatments significantly more affordable across the country.
A Massive Relief for Patients
The government's decision to cap trade margins at 30 per cent of the Maximum Retail Price (MRP) for non-scheduled anti-cancer drugs is expected to trigger a dramatic drop in costs. According to official sources, this measure could lead to a reduction of up to 70 per cent in the MRP of certain expensive medications.
The scale of the impact is substantial. It is estimated that this pricing overhaul could result in annual savings of approximately Rs 2,500 crore for the public. The proposed regulations are designed to be comprehensive, covering:
- Branded and generic medicines
- Domestic and imported drugs
- Patented and non-patented anti-cancer treatments
AIOCD Demands Transparency at the Source
While celebrating the move, the AIOCD has also used the opportunity to advocate for systemic changes in how medicine prices are set. AIOCD President JS Shinde and General Secretary Rajiv Singhal emphasized that the responsibility for high prices often lies much earlier in the supply chain.
“Rationalisation of cancer medicine prices is an important step in the larger interest of patients,” stated Rajiv Singhal. He noted that the organisation has consistently pushed for a transparent mechanism for MRP fixation, specifically requesting the implementation of a 42 per cent criterion over the Price to Retailer (PTR) where appropriate.
The association pointed out a critical distinction in the supply chain: since the MRP is determined and printed by the pharmaceutical manufacturer, any excessive mark-ups must be addressed at the source. The AIOCD argued that genuine chemists and distributors should not be unfairly blamed for high prices that are decided "upstream" by manufacturers.
A Precedent for Other Essential Medicines
The current move follows a successful precedent set in 2019, when a similar principle was applied to 42 non-scheduled anti-cancer medicines, leading to a significant price drop for hundreds of brands. The AIOCD is now urging the government to extend this same scientific and uniform approach to other high-cost, essential medicines where disproportionate MRPs are observed.
The apex national trade association, which represents over 12.4 lakh retail chemists, pharmacists, and distributors, is calling for a balanced national policy. Such a policy, they argue, must simultaneously ensure:
- Affordability for patients
- Rational and transparent MRP fixation
- Reasonable and sustainable trade margins
- Uninterrupted availability of life-saving drugs
- Fairness across the entire pharmaceutical supply chain